RESUMEN
Nogo protein is the fourth member of reticulin famity. Nogo mRNA produced by encoding gene transcription, forms three different RNA transcripts due to different promoter and splicing modes, namely Nogo-A, Nogo-B and Nogo-C protein. Nogo protein was first found in the central nervous system, and then proved to be widely expressed in peripheral tissues such as heart, liver and vascular endothelium. Studies have shown that Nogo protein can participate in the regulation of myocardial fibrosis through RhoA/Rho-associated kinase(ROCK) pathway, endoplasmic reticulum stress, Sce61 a and other signaling pathways. In this paper, the relationship between Nogo-A, Nogo-B, Nogo-C and myocardial fibrosis is briefly introduced.
RESUMEN
As a member of the reticulin family, Nogo is mainly involved in processes such as tissue regeneration, apoptosis and tumor growth after tissue injury. Cardiovascular disease is one of the main diseases that threaten human health at present. In recent years, research on Nogo in the cardiovascular system has become increasingly extensive. Changes in the expression of Nogo during myocardial fibrosis, myocardial cell apoptosis and vascular remodeling suggest that it may play a certain role. This article reviews the distribution of Nogo in the heart and its role in cardiovascular disease, in order to reveal its possible role and mechanism in cardiovascular diseases.
RESUMEN
OBJECTIVE: To probe the effect and mechanism of Compound Glycyrrhizin in treating AIDS. METHODS: Forty AIDS patients were randomly divided into a treatment group and a control group, both treated with HAART. In addition, the former was given Compound Glycyrrhizin for 6 months, and the CD4+ T count and the expressions of CD8+ and HLA-DR on the surface of peripheral blood lymphocytes (PBL) were studied before and after the treatment. RESULTS: After 6 months of treatment, the expressions of CD8+ and CD38+ of PBL in the treatment group [(6.6 +/- 2.1)%] were found lower than in the control [(11.4 +/- 3.8)%] (t = 5.043, P < 0.01) and CD4+ T count [(243.6 +/- 91.2) x 10(6)/L vs (170.8 +/- 55.7) x 10(6)/L] rose more significantly (t = 3.045, P < 0.01). CONCLUSION: Compound Glycyrrhizin can lower the expression of active T-lymphocyte subset, inhibit HIV and help immune reconstitution.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/inmunología , Fármacos Anti-VIH/uso terapéutico , Ácido Glicirrínico/uso terapéutico , Subgrupos de Linfocitos T/efectos de los fármacos , ADP-Ribosil Ciclasa 1/biosíntesis , Adolescente , Adulto , Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Femenino , Antígenos HLA-DR/biosíntesis , Humanos , Masculino , Persona de Mediana Edad , Subgrupos de Linfocitos T/inmunologíaRESUMEN
OBJECTIVE: To investigate the coreceptors CCR5 and CXCR4 expressions on the peripheral blood T lymphocytes in HIV/AIDS patients, with an analysis of their clinical value. METHODS: Thirty HIV/AIDS patients and 16 normal controls were selected and flow-cytometry was used to detect the coreceptors CCR5 and CXCR4 expressions in whole blood samples taken from the patients and controls. An analysis was made of the correlation of the coreceptor expression with CD4 T cell counts and the activation of CD4+/ CD8+ T cells (HLA-DR+/CD38+). RESULTS: The CCR5 expression on CD8+ lymphocytes and the CXCR4 expression on the CD4+/ CD8+ T lymphocytes of the HIV/AIDS group were higher than those of the normal controls (P < 0.01). The CCR5 and CXCR4 expressions on the CD4+/CD8+ T lymphocytes of the HIV/AIDS patients was significantly correlated with the activation of CD4+/CD8+ T cells (HLA-DR+/CD38+) (P < 0.05). CONCLUSION: The expressions of CCR5 and CXCR4 are significantly correlated with the immune system reaction to HIV and the disease progression in HIV infected patients.